Magnetar Financial LLC Makes New Investment in Drugs Made In America Acquisition II Corp. $DMII

Magnetar Financial LLC purchased a new position in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 2,700,000 shares of the company’s stock, valued at approximately $26,730,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Periscope Capital Inc. bought a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter worth about $2,628,000. Deltec Asset Management LLC bought a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter worth approximately $495,000. Wealthspring Capital LLC bought a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter worth approximately $4,049,000. Wolverine Asset Management LLC bought a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter worth approximately $10,521,000. Finally, HighTower Advisors LLC bought a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter worth approximately $7,817,000.

Drugs Made In America Acquisition II Stock Performance

NASDAQ DMII opened at $10.09 on Wednesday. The stock has a 50 day simple moving average of $10.04. Drugs Made In America Acquisition II Corp. has a 12 month low of $9.86 and a 12 month high of $10.09.

Wall Street Analysts Forecast Growth

DMII has been the topic of a number of research reports. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.